Current uses of isolated limb perfusion in the clinic and a model system for new strategies (Q33187671)

23 July 2017

1 reference

title

Current uses of isolated limb perfusion in the clinic and a model system for new strategies (English)

1 reference

23 July 2017

1

Alexander M M Eggermont

1 reference

23 July 2017

Johannes H W de Wilt

2

1 reference

PubMed ID

12850194

23 July 2017

Timo L M ten Hagen

series ordinal

3

1 reference

23 July 2017

1 July 2003

1 reference

Lancet Oncology Commission

23 July 2017

1 reference

23 July 2017

4

1 reference

23 July 2017

7

1 reference

23 July 2017

429-437

1 reference

Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Systemic leakage during isolated limb perfusion for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Optimization of isolated hyperthermic limb perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Selective heat sensitivity of cancer cells. Biochemical and clinical studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

A retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

A retrospective comparative study evaluating the results of mild hyperthermic versus controlled normothermic perfusion for recurrent melanoma of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Hyperthermic antiblastic perfusion in the treatment of cancer of the extremities.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Hyperthermic isolated limb perfusion for malignant melanoma: response and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Regional therapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Chemotherapy of Sarcomas of the Limbs by Regional Perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Regional perfusion for malignant melanoma and soft tissue sarcoma: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Treatment of recurrent sarcoma of the extremities by isolated limb perfusion using tumor necrosis factor alpha and melphalan.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Soft tissue limb sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable sSewart-Treves lymphangiosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

31P magnetic resonance spectroscopy as predictor of clinical response in human extremity sarcomas treated by single dose TNF-alpha + melphalan isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion with TNF alpha and melphalan in a rat osteosarcoma model: a new anti-tumour approach

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Reduction of interstitial fluid pressure after TNF-alpha treatment of three human melanoma xenografts

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Assessment of the role of neutrophils on the antitumor effect of TNFalpha in an in vivo isolated limb perfusion model in sarcoma-bearing brown Norway rats

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

TNF is here to stay--revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901141-0

7 January 2021

10.1016/S1470-2045(03)01141-0

Identifiers

DOI

1 reference

release_mcqyg4uzwjgcfffqyepyz2mwje

23 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mcqyg4uzwjgcfffqyepyz2mwje

24 November 2022

mapped directly with Wikidata item

PubMed ID

12850194

1 reference

PubMed ID

12850194